JMP Securities Reaffirms “Market Outperform” Rating for Notable Labs (NASDAQ:NTBL)

JMP Securities reiterated their market outperform rating on shares of Notable Labs (NASDAQ:NTBL) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, Chardan Capital lowered their price objective on shares of Notable Labs from $9.00 to $7.00 and set a buy rating for the company in a research note on Monday.

Notable Labs Price Performance

NASDAQ:NTBL opened at $0.96 on Monday. Notable Labs has a 1-year low of $0.83 and a 1-year high of $11.20. The business has a 50-day simple moving average of $1.44. The stock has a market capitalization of $2.13 million, a price-to-earnings ratio of -0.26 and a beta of 0.77. The company has a current ratio of 5.65, a quick ratio of 5.65 and a debt-to-equity ratio of 0.02.

Institutional Trading of Notable Labs

An institutional investor recently bought a new position in Notable Labs stock. Industry Ventures L.L.C. purchased a new stake in shares of Notable Labs, Ltd. (NASDAQ:NTBL) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs comprises about 0.6% of Industry Ventures L.L.C.’s holdings, making the stock its 6th biggest position. Industry Ventures L.L.C. owned about 9.21% of Notable Labs at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.48% of the company’s stock.

Notable Labs Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.